Critical Comparison: Seattle Genetics (NASDAQ:SGEN) and Cellectis (CLLS)

Cellectis (NASDAQ: CLLS) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation.


This table compares Cellectis and Seattle Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellectis -217.25% -30.66% -25.66%
Seattle Genetics -26.03% -32.49% -24.96%

Valuation & Earnings

This table compares Cellectis and Seattle Genetics’ gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cellectis $56.46 million 20.71 -$67.25 million ($2.41) -13.50
Seattle Genetics $482.25 million 17.61 -$125.53 million ($0.88) -61.11

Cellectis has higher earnings, but lower revenue than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Cellectis, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

17.2% of Cellectis shares are held by institutional investors. Comparatively, 91.0% of Seattle Genetics shares are held by institutional investors. 16.4% of Cellectis shares are held by insiders. Comparatively, 34.7% of Seattle Genetics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Cellectis and Seattle Genetics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellectis 0 1 5 0 2.83
Seattle Genetics 0 9 10 0 2.53

Cellectis currently has a consensus price target of $39.83, suggesting a potential upside of 22.41%. Seattle Genetics has a consensus price target of $64.00, suggesting a potential upside of 19.00%. Given Cellectis’ stronger consensus rating and higher probable upside, equities analysts clearly believe Cellectis is more favorable than Seattle Genetics.

Risk & Volatility

Cellectis has a beta of 2.07, meaning that its stock price is 107% more volatile than the S&P 500. Comparatively, Seattle Genetics has a beta of 2.08, meaning that its stock price is 108% more volatile than the S&P 500.


Seattle Genetics beats Cellectis on 8 of the 13 factors compared between the two stocks.

Cellectis Company Profile

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development and commercialization of rational genome engineering technologies. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. The Company also offers rational inverse genetics and targeting recombination tools. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Seattle Genetics Company Profile

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Company is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company’s marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC). In addition to ADCETRIS, the Company’s pipeline includes other clinical-stage ADC programs, such as ASG-22ME, SGN-LIV1A, SGN-CD19A, SGN-CD19B, SGN-CD123A, SGN-352A, and ASG-15ME, as well as two immuno-oncology agents, SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology, and SGN-2FF, which is a small molecule. It also has multiple preclinical and research-stage programs that employ its technologies, including SGN-CD48A and a preclinical ADC. ADCETRIS is an ADC comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent.

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with's FREE daily email newsletter.

Leave a Reply